European Respiratory Society

Congress 2018

Letter from The Editor

Landmark triple therapy trials

ICS: to use or not to use?

MABA, and novel LAMA

Macrolide antibiotics and trial with azithromycin

Introduction

From clinical, anatomical, pathophysiological, and inflammatory subsets to molecular pathways

Treatments targeting type2-inflammation

Late-breaking biologics

Endoscopic treatment of emphysema

Endoscopic treatment of asthma

Endoscopic treatment of chronic bronchitis

Risk stratification

New therapeutic targets: moving form pre-clinical data to phase 2 studies

Balloon pulmonary angioplasty for CTEPH

IPF introduction and Pentraxin-2

Nintedanib and sildenafil

Gastroesophageal reflux, IPF and lessons learned

EGFR-targeted treatments

ALK inhibition, guidelines, liquid biopsies, and immunotherapy

Brain metastases, lung cancer and interstitial lung disease

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.